Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.58+0.20 (+3.72%)
At close: 04:00PM EDT
5.58 0.00 (0.00%)
After hours: 07:53PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.38
Open5.51
Bid5.58 x 800
Ask5.61 x 1800
Day's Range5.09 - 5.67
52 Week Range3.14 - 9.53
Volume1,618,546
Avg. Volume497,250
Market Cap641.7M
Beta (5Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say

    On Wednesday, Immunovant Inc (NASDAQ: IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd's (NASDAQ: ROIV) Investor Day. IMVT-1402 is a new anti-FcRn monoclonal antibody that matches batoclimab's IgG lowering without affecting albumin and LDL. HC Wainwright says the addition of IMVT-1402 broadens the anti-FcRn franchise. The analyst maintains a Buy rating with a price target of $16. Roivant is leveraging data and learnings from batoclimab studies to accelerate IMVT-1402's develop

  • Zacks

    Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why

    Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

  • Zacks

    Immunovant, Inc. (IMVT) Upgraded to Buy: Here's Why

    Immunovant, Inc. (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Advertisement
Advertisement